At the news
? BULLISHIMPACT 6/10 8-K filed Nov 9, 2026 at 08:31 ET
Vir Biotechnology announced positive Phase 3 ECLIPSE 1 topline results for its combination regimen of elebsiran and tobevibart in chronic hepatitis delta, meeting the primary endpoint with a 44% response rate vs 0% in the delayed treatment group (p<0.0001). Expanded Phase 2 SOLSTICE data showed 100% of patients reaching undetectable viremia at Week 96, and an exploratory finite treatment analysis showed all 10 patients who discontinued treatment achieved SVR12. The data were presented at AASLD on November 8, 2026.
- Phase 3 ECLIPSE 1 primary endpoint met: 44% undetectable virus + ALT normalization at Week 48 vs 0% in delayed treatment group (p<0.0001)
- Key secondary endpoint: 79% undetectable virus at Week 48 vs 0% (p<0.0001)
- 100% virologic response (HDV RNA TND or 2 log10 reduction) in active arm vs 0% in control
- Phase 2 SOLSTICE Week 96: 100% (28/28) of patients on combination therapy reached undetectable viremia
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access